NASDAQ · INCY
Incyte Corp.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for INCY has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-4.27 | $-3.22 | $-5.72 | 7 |
| Dec 2026 | $1.62 | $1.93 | $1.26 | 8 |
| Mar 2027 | $1.56 | $1.67 | $1.49 | 4 |
| Jun 2027 | $1.96 | $2.08 | $1.86 | 4 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · Zacks · RTTNews · MarketBeat- Fintel · 2 h agoIncyte Corporation Reports Third Quarter 2026 Total Revenue of $1.56 billionIncyte Corporation reported its financial results for the third quarter ended September 30, 2026, with total revenue of $1.56 billion and total net sales of $1.32 billion, representing an increase of 14% for each compared to the third quarter of 2025. Net sales of Jakafi/Jakafi X
- Zacks · 5 h agoIncyte (INCY) Reports Q3 Earnings: What Key Metrics Have to SayAlthough the revenue and EPS for Incyte (INCY) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- RTTNews · 5 h agoIncyte Posts Loss In Q3, But Revenue Rises; Lifts Sales Outlook(RTTNews) – Incyte Corp. (INCY), a biopharmaceutical company, Thursday reported a third-quarter loss compared with a profit a year earlier, primarily due to a one-time research and development expense related to its acquisition of Vega Therapeutics. The company raised its full-ye
- Zacks · 6 h agoIncyte (INCY) Reports Q3 Loss, Beats Revenue EstimatesIncyte (INCY) delivered earnings and revenue surprises of +9.77% and +5.06%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · 7 h agoIncyte Q3 26 Earnings Conference Call At 8:00 AM ET(RTTNews) – Incyte Corporation (INCY) will host a conference call at 8:00 AM ET on October 29, 2026, to discuss Q3 26 earnings results.
- MarketBeat · Oct 26, 10:02 PM EDTIncyte Highlights Promising Early Data for ’890 and ’734 in GI CancersCan Incyte Deliver on 447% EPS Forecasts and Pipeline Hype?Incyte (NASDAQ:INCY) presented updated clinical data and development plans for two experimental solid-tumor programs at ESMO in Madrid: INCA33890, a TGFβR2-by-PD-1 bispecific antibody known as “’890,” and INCB161734, a KR
- Zacks · Oct 26, 10:25 AM EDTIncyte & Genmab Collaborate to Develop a New Colorectal Cancer TherapyINCY and GMAB team up to evaluate a three-drug combination for first-line treatment of KRAS G12D-mutated metastatic colorectal cancer.
- Zacks · Oct 26, 9:00 AM EDTSyndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseSyndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- RTTNews · Oct 24, 8:27 AM EDTGenmab, Incyte Partner On Trial Of Petosemtamab Combination In KRAS G12D-Mutated Colorectal Cancer(RTTNews) – Genmab A/S (GMAB) and Incyte (INCY) have entered into a clinical trial collaboration to evaluate a novel combination therapy for patients with metastatic colorectal cancer (mCRC) harboring a KRAS G12D mutation, a population with significant unmet medical needs.
- Zacks · Oct 23, 8:25 AM EDTIncyte Gears Up to Report Q3 Earnings: Will Results Disappoint?INCY's Q3'26 results hinge on Jakafi's strong sales, Opzelura's growth and rising royalties, while higher operating expenses may pressure earnings.
- Zacks · Oct 22, 9:00 AM EDTAnalysts Estimate Incyte (INCY) to Report a Decline in Earnings: What to Look Out forIncyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- RTTNews · Oct 16, 3:02 PM EDTFDA Drug Approvals In September 2026(RTTNews) – The U.S. Food and Drug Administration (FDA) approved 13 drugs in September 2026, spanning first-in-class therapies, treatments for rare diseases, and new options for patients with serious conditions.With the month yielding a mix of new therapies and expanded treatment
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Incyte Corp. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.